Successful experience in treating primary cutaneous anaplastic large cell lymphoma occuring with common lesions of the skin and lung tissue

Cover Page


Cite item

Full Text

Abstract

The aim of the study is to present a successful case in treating primary cutaneous anaplastic large cell lymphoma (PCALCL) occurring with common lesions of the skin and lung tissue.
Materials and methods. For the verification of the diagnosis in a patient with three types of skin elements (spot, thin plaque with and without ulceration), differential diagnosis was performed between ulcerative pyoderma gangrenosum, PCALCL, large-cell transformation of mycosis fungoides, and secondary skin lesions under the nodal ALK-negtaive ALCL. A complex of studies, including histological, immunohisto - chemical, cytogenetic studies of skin tumor biopsy, allowed the verification of the PCALCL diagnosis. For the treatment of the patient, intensive induction chemotherapy was used followed by high-dose consolidation and autologous transplantation of hematopoietic stem cells.
Results. The selected treatment tactics allowed a long-term complete remission of the disease to be achieved in a patient from the poor prognosis group.
Conclusion. An algorithm for the differential diagnosis and tactics of treating is presented for a patient with primary anaplastic large cell lymphoma with a widespread skin lesion and extradermal foci.

About the authors

N. G. Chernova

National Research Center for Hematology

Author for correspondence.
Email: ngchernova@mail.ru

Cand. Sci. (Med.), Hematologist Doctor

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

D. S. Badmazhapova

National Research Center for Hematology

Email: darima-doctor@mail.ru

Post-Graduate Student

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

A. M. Kovrigina

National Research Center for Hematology

Email: kovrigina.alla@gmail.com

Dr. Sci. (Biol.), Laboratory Head

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

A. E. Karamova

State Scientific Center of Dermatovenereology and Cosmetology

Email: karamova@cnikvi.ru

Cand. Sci. (Med.), Departmental Head, Department of Dermatology

Korolenko str., 3, building 6, 107076, Moscow, Russian Federation

Россия

A. A. Vorontsova

State Scientific Center of Dermatovenereology and Cosmetology

Email: nastasia08@bk.ru

Junior Researcher, Department of Dermatology

Korolenko str., 3, building 6, 107076, Moscow, Russian Federation

Россия

M. N. Sinitcina

National Research Center for Hematology

Email: msini@mail.ru

Researcher

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

Yu. V. Sidorova

National Research Center for Hematology

Email: iouliavl@rambler.ru

Cand. Sci. (Med.), Senior Researcher

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

L. A. Grebenyuk

National Research Center for Hematology

Email: lyuba.grebenyuk@yandex.ru

Leading Molecular Biology Specialist

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

M. A. Nefedova

State Scientific Center of Dermatovenereology and Cosmetology

Email: nefedova.maria.arb@gmail.com

Junior Researcher, Dapartment of Dermatology

Korolenko str., 3, building 6, 107076, Moscow, Russian Federation

Россия

L. F. Znamenskaya

State Scientific Center of Dermatovenereology and Cosmetology

Email: znaml@cnikvi.ru

Dr. Sci. (Med.), Leading Researcher, Department of Dermatology

Korolenko str., 3, building 6, 107076, Moscow, Russian Federation

Россия

E. E. Zvonkov

National Research Center for Hematology

Email: dr.zvonkov@gmail.com

Dr. Sci. (Med.), Departmental Head

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

V. G. Savchenko

National Research Center for Hematology

Email: director@blood.ru

RAS Academician, General Director

Zykovsky Novy proezd, 4, Moscow, 125167, Russian Federation

Россия

References

  1. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer / T-cell lymphoma study: pathology findings and clinical outcomes. International T-Cell Lymphoma Project. J Clin Oncol. 2008 Sep 1;26(25):4124–4130. doi: 10.1200/JCO.2008.16.4558
  2. Swerdlow S. H., Campo E., Harris N. L., Jaffe E. S., Pileri S. A., Stein H., Thiele J., Arber D. A., Hasserjian R. P., Le Beau M. M., Orazi A., Siebert R. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2017:395–396.
  3. Kadin M. E., Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003;40(3):244–256.
  4. Bekkenk M. W., Geelen F. A., van Voorst Vader P. C., Heule F., Geerts M. L., van Vloten W. A., Meijer C. J., Willemze R. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–3661.
  5. Stein H., Foss H. D., Dürkop H., Marafioti T., Delsol G., Pulford K., Pileri S., Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–3695.
  6. Paulli M., Berti E., Rosso R., Boveri E., Kindl S., Klersy C., Lazzarino M., Borroni G., Menestrina F., Santucci M. et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin — clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13(6):1343–1354. doi: 10.1200/JCO.1995.13.6.1343
  7. Kempf W., Pfaltz K., Vermeer M. H., Cozzio A., Ortiz-Romero P. L., Bagot M. et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–4035. doi: 10.1182/blood-2011-05-351346
  8. Willemze R., Jaffe E. S., Burg G., Cerroni L., Berti E., Swerdlow S. H. et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785.
  9. Dogan A., Morice W. G. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol. 2004;127(2):140–154. doi: 10.1111/j.1365-2141.2004.05144.x
  10. Burg G., Kempf W., Kazakov D. V., Dummer R., Frosch P. J., Lange-Ionescu S., Nishikawa T., Kadin M. E. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br J Dermatol. 2003;148(3):580–586.
  11. Felgar R. E., Macon W. R., Kinney M. C., Roberts S., Pasha T., Salhany K. E. TIA-1 expression in lymphoid neoplasms. Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol. 1997;150(6):1893–1900.
  12. Boulland M. L., Wechsler J., Bagot M., Pulford K., Kanavaros P., Gaulard P. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology. 2000;36(2):136–144.
  13. Молочков А. В., Ковригина А. М., Кильдюшевский А. В., Караулов А. В. Лимфомы кожи. М.: Бином, 2012:44–46. [Molochkov A. V., Kovrigina A. M., Kildyushevsky A. V., Karaulov A. V. Skin Lymphoma. Moscow: Binom, 2012:44–46. (In Russ.)].
  14. Macgrogan G., Vergier B., Dubus P., Beylot-Barry M., Belleannee G., Delaunay M. M., Eghbali H., Beylot C., Rivel J., Trojani M., Vital C., DeMascarel A., Bloch B., Merlio J. P. CD30-positive cutaneous large cell lymphomas. A comparative study of clinic pathologic and molecular features of 16 cases. Am J Clin Pathol. 1996;105(4):440–450.
  15. Laharanne E., Oumouhou N., Bonnet F., Carlotti M., Gentil C., Chevret E., Jouary T., Longy M., Vergier B., Beylot-Barry M., Merlio J. P. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol. 2010;130(2):563–575. doi: 10.1038/jid.2009.270
  16. van Kester M. S., Tensen C. P., Vermeer M. H., Dijkman R., Mulder A. A., Szuhai K., Willemze R., van Doorn R. Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol. 2010;130(6):1707–1718. doi: 10.1038/jid.2010.8
  17. Wada D. A., Law M. E., Hsi E. D., Dicaudo D. J., Ma L., Lim M. S. et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol. 2011;24(4):596–605. doi: 10.1038/modpathol.2010.225
  18. Pham-Ledard A., Prochazkova-Carlotti M., Laharanne E., Vergier B., Jouary T., Beylot-Barry M., Merlio J. P. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol. 2010;130(3):816–825. doi: 10.1038/jid.2009.314
  19. Vasmatzis G., Johnson S. H., Knudson R. A., Ketterling R. P., Braggio E., Fonseca R. et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120(11):2280–2289. doi: 10.1182/blood-2012-03-419937
  20. Parrilla Castellar E. R., Jaffe E. S., Said J. W., Swerdlow S. H., Ketterling R. P., Knudson R. A. et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood 2014;124(9):1473–1480. doi: 10.1182/blood-2014-04-571091
  21. Prochazkova M., Chevret E., Beylot-Barry M., Sobotka J., Vergier B., Delaunay M., Turmo M., Ferrer J., Kuglik P., Merlio J. P. Chromosomal imbalances: a hallmark of tumour relapse in primary cutaneous CD30+ T-cell lymphoma. J Pathol. 2003;201(3):421–429. doi: 10.1002/path.1469
  22. Younes A., Bartlett N. L., Leonard J. P., Kennedy D. A., Lynch C. M., Sievers E. L., Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821. doi: 10.1056/NEJMoa1002965
  23. Pro B., Advani R., Brice P., Bartlett N. L., Rosenblatt J. D., Illidge T., Matous J., Ramchandren R., Fanale M., Connors J. M., Fenton K., Huebner D., Pinelli J. M., Kennedy D. A., Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–2717. doi: 10.1182/blood-2017-05-780049
  24. Duvic M., Reddy S. A., Pinter-Brown L., Korman N. J., Zic J., Kennedy D. A., Lorenz J., Sievers E. L., Kim Y. H. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009 Oct 1;15(19):6217–6224. doi: 10.1158/1078-0432.CCR-09-0162
  25. Liu H. L., Hoppe R. T., Kohler S., Harvell J. D., Reddy S., Kim Y. H. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049–1058. doi: 10.1016/S0190
  26. Benner M. F., Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol. 2009;145(12):1399–1404. doi: 10.1001/archdermatol.2009.280
  27. Woo D. K., Jones C. R., Vanoli-Storz M. N., Kohler S., Reddy S., Advani R., Hoppe R. T., Kim Y. H. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667–674. doi: 10.1001/archdermatol.2009.74
  28. Hapgood G., Pickles T., Sehn L. H., Villa D., Klasa R., Scott D. W., Gerrie A. S., Gascoyne R. D., Slack G. W., Parsons C., Morris J. W., Connors J. M., Savage K. J. Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience. Br J Haematol. 2017;176(2):234–240. doi: 10.1111/bjh.14404
  29. Doukaki S., Aricò M., Bongiorno MR.A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris. Case Rep Dermatol. 2009;1(1):60–65. doi: 10.1159/000249148
  30. Baser S., Onn A., Lin E., Morice R. C., Duvic M. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer. 2007;109(8):1550–1555. doi: 10.1002/cncr.22567
  31. Савченко В. Г. (ред.) Алгоритмы диагностики и протоколы лечения заболеваний системы крови. М.: Практика, 2018. Т. 2. [Savchenko V. G. (ed.) Diagnostic algorithms and protocols for the treatment of diseases of the blood system. Moscow: Praktika, 2018. V. 2. (In Russ.)]
  32. Чернова Н. Г., Звонков Е. Е., Бадмажапова Д. С., Синицына М. Н., Гребенюк Л. А., Сидорова Ю. В., Костина И. Э., Ковригина А. М., Обухова Т. Н., Судариков А. Б., Савченко В. Г. Первый опыт применения комбинации брентуксимаба ведотина с интенсивной химиотерапией у первичной больной анапластической крупноклеточной лимфомой: обзор литературы и описание клинического случая. Терапевтический архив. 2018;90(7):77–81. [Chernova N. G., Zvonkov E. E., Badmazhapova D. S., Sinitsyna M. N., Grebenyuk L. A., Sidorova Y. V., Kostina I. E., Kovrigina A. M., Obukhova T. N., Sudarikov A. B., Savchenko V. G. First experience of using Brentuximabvedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature. Terapevticheskij Arhiv. 2018;90(7):33–37 (In Russ.)]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Chernova N.G., Badmazhapova D.S., Kovrigina A.M., Karamova A.E., Vorontsova A.A., Sinitcina M.N., Sidorova Y.V., Grebenyuk L.A., Nefedova M.A., Znamenskaya L.F., Zvonkov E.E., Savchenko V.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies